← Back to Search

Checkpoint Inhibitor

ipilimumab for Uveal Melanoma

Phase 1 & 2
Waitlist Available
Research Sponsored by David Minor, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5years
Awards & highlights

Study Summary

This trial is testing whether combining immunotherapy with radiation therapy is more effective than immunotherapy alone for treating uveal melanoma that has spread to the liver.

Eligible Conditions
  • Uveal Melanoma
  • Liver Metastases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
safety and tolerability of sequential selective internal radiation with Yttrium90 followed by immunotherapy with ipilimumab and nivolumab.
Secondary outcome measures
Correlation of tissue markers and response to immunotherapy
Immunotherapy
Preliminary clinical efficacy
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: hepatic radiation followed by immunotherapyExperimental Treatment3 Interventions
SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ipilimumab
FDA approved
Nivolumab
FDA approved

Find a Location

Who is running the clinical trial?

David Minor, MDLead Sponsor
California Pacific Medical CenterOTHER
12 Previous Clinical Trials
8,144 Total Patients Enrolled
Jefferson Medical College of Thomas Jefferson UniversityOTHER
12 Previous Clinical Trials
13,844 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the normal prescription for SIR-Spheres® Yttrium 90?

"SIR-Spheres® Yttrium 90 is an effective solution for previous anti-angiogenic therapy, malignant neoplasms, and cases of unresectable melanoma."

Answered by AI

Is this research endeavor actively seeking participants?

"This trial is no longer accepting new patients, with the last modification to its posting being made on April 15th 2021. If you are still in search of a clinical trial, there are presently 1374 neoplasm metastasis studies and 765 SIR-Spheres® Yttrium 90 trials actively recruiting participants."

Answered by AI

How many participants are engaged in this experiment?

"This clinical trial has concluded its recruitment phase, having been posted on October 10th 2016 and last updated April 15th 2021. Fortunately, there are currently 1374 studies actively enrolling patients with neoplasm metastasis and 765 trials looking for participants to try SIR-Spheres® Yttrium 90."

Answered by AI

Could you please provide an overview of any other research that has utilized SIR-Spheres® Yttrium 90?

"SIR-Spheres® Yttrium 90 is currently being tested in 765 active trials, 86 of which are at the Phase 3 level. The bulk of them originate from Pittsburgh, Pennsylvania though 42755 other sites have opened up for clinical studies involving SIR-Spheres® Yttrium 90."

Answered by AI
~3 spots leftby Mar 2025